Literature DB >> 24389043

MLK3 regulates fMLP-stimulated neutrophil motility.

Oksana Polesskaya1, Christopher Wong2, Luis Lebron3, Jeffrey M Chamberlain3, Harris A Gelbard4, Val Goodfellow5, Minsoo Kim6, John L Daiss7, Stephen Dewhurst8.   

Abstract

INTRODUCTION: Mixed lineage kinase 3 (MLK3) is part of the intracellular regulatory system that connects extracellular cytokine or mitogen signals received through G-protein coupled receptors to changes in gene expression. MLK3 activation stimulates motility of epithelial cells and epithelial-derived tumor cells, but its role in mediating the migration of other cell types remains unknown. Since neutrophils play a crucial role in innate immunity and contribute to the pathogenesis of several diseases, we therefore examined whether MLK3 might regulate the motility of mouse neutrophils responding to a chemotactic stimulus, the model bacterial chemoattractant fMLP.
METHODS: The expression of Mlk3 in mouse neutrophils was determined by immunocytochemistry and by RT-PCR. In vitro chemotaxis in a gradient of fMLP, fMLP-stimulated random motility, fMLP-stimulated F-actin formation were measured by direct microscopic observation using neutrophils pre-treated with a novel small molecule inhibitor of MLK3 (URMC099) or neutrophils obtained from Mlk3-/- mice. In vivo effects of MLK3 inhibition were measured by counting the fMLP-induced accumulation of neutrophils in the peritoneum following pre-treatment with URMC099 in wild-type C57Bl/6 or mutant Mlk3-/- mice.
RESULTS: The expression of Mlk3 mRNA and protein was observed in neutrophils purified from wild-type C57Bl/6 mice but not in neutrophils from mutant Mlk3-/- mice. Chemotaxis by wild-type neutrophils induced by a gradient of fMLP was reduced by pre-treatment with URMC099. Neutrophils from C57Bl/6 mice pretreated with URMC099 and neutrophils from Mlk3-/- mice moved far less upon fMLP-stimulation and did not form F-actin as readily as untreated neutrophils from C57Bl/6 controls. In vivo recruitment of neutrophils into the peritoneum by fMLP was significantly reduced in wild-type mice treated with URMC099, as well as in untreated Mlk3-/- mice-thereby confirming the role of MLK3 in neutrophil migration.
CONCLUSIONS: Mlk3 mRNA is expressed in murine neutrophils. Genetic or pharmacologic inhibition of MLK3 blocks fMLP-mediated motility of neutrophils both in vitro and in vivo, suggesting that MLK3 may be a therapeutic target in human diseases characterized by exuberant neutrophil migration.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AD; AKT; APC; CRIB; Chemotaxis; DMSO; EDTA; ERK; EtBr; FITC; G-protein coupled receptor; GAPDH; GPCR; GTP; HBSS; Hank's buffered salt solution; ICAM; JIP; JNK; JNK interacting protein; MKK; MLK3; Mixed lineage kinase 3; Mouse; N-formyl-l-methionyl-l-leucyl-l-phenylalanine; Neutrophil; PBS; PCR; PE; PEG; PI3K; RT-PCR; SH3; Src homology domain 3; TBS; TNF; accumulated distance; allophycocyanin; c-jun N-terminal protein kinase; cdc42/Rac-interactive binding; dimethyl sulfoxide; ethidium bromide; ethylenediaminotetraacetic acid; extracellular signal-related kinase; fMLP; fluorescein isothiocyanate; glyceraldehyde-3-phosphate dehydrogenase; guanosine triphosphate; intercellular adhesion molecule; mitogen-activated protein kinase kinase; mixed lineage kinase 3; phosphate-buffered saline; phosphoinositide-3-kinase; phycoerythrin; polyethyleneglycol; polymerase chain reaction; protein kinase B; reverse transcription-polymerase chain reaction; tris-buffered saline; tumor necrosis factor

Mesh:

Substances:

Year:  2014        PMID: 24389043      PMCID: PMC3946811          DOI: 10.1016/j.molimm.2013.11.016

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  41 in total

1.  Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components.

Authors:  D Nihalani; D Meyer; S Pajni; L B Holzman
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

2.  Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury.

Authors:  Quan-Guang Zhang; Xiao-Tian Wang; Dong Han; Xiao-Hui Yin; Guang-Yi Zhang; Tian-Le Xu
Journal:  J Neurochem       Date:  2006-07-11       Impact factor: 5.372

3.  MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive metastasis.

Authors:  Jian Chen; Kathleen A Gallo
Journal:  Cancer Res       Date:  2012-06-13       Impact factor: 12.701

4.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

5.  Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3.

Authors:  I W Leung; N Lassam
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

Review 6.  Mixed-lineage kinase control of JNK and p38 MAPK pathways.

Authors:  Kathleen A Gallo; Gary L Johnson
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

7.  Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.

Authors:  Hua Zhang; Wei Wu; Yan Du; Sarah J Santos; Susan E Conrad; Jack T Watson; Nicholas Grammatikakis; Kathleen A Gallo
Journal:  J Biol Chem       Date:  2004-03-04       Impact factor: 5.157

Review 8.  Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils.

Authors:  Rita Selvatici; Sofia Falzarano; Adriano Mollica; Susanna Spisani
Journal:  Eur J Pharmacol       Date:  2006-03-03       Impact factor: 4.432

9.  The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.

Authors:  Daniel F Marker; Marie-Ève Tremblay; Jenna M Puccini; Justin Barbieri; Mary A Gantz Marker; Colin J Loweth; E Chris Muly; Shao-Ming Lu; Val S Goodfellow; Stephen Dewhurst; Harris A Gelbard
Journal:  J Neurosci       Date:  2013-06-12       Impact factor: 6.167

10.  Mixed-lineage kinase 3 phosphorylates prolyl-isomerase Pin1 to regulate its nuclear translocation and cellular function.

Authors:  Velusamy Rangasamy; Rajakishore Mishra; Gautam Sondarva; Subhasis Das; Tae Ho Lee; Joanna C Bakowska; Guri Tzivion; James S Malter; Basabi Rana; Kun Ping Lu; Anumantha Kanthasamy; Ajay Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

View more
  12 in total

1.  The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.

Authors:  Gang Zhang; Dongwei Guo; Prasanta K Dash; Mariluz Araínga; Jayme L Wiederin; Nicole A Haverland; Jaclyn Knibbe-Hollinger; Andrea Martinez-Skinner; Pawel Ciborowski; Val S Goodfellow; Tadeusz A Wysocki; Beata J Wysocki; Larisa Y Poluektova; Xin-Ming Liu; JoEllyn M McMillan; Santhi Gorantla; Harris A Gelbard; Howard E Gendelman
Journal:  Nanomedicine       Date:  2015-10-22       Impact factor: 5.307

2.  Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.

Authors:  Divya Prakash Gnanadhas; Prasanta K Dash; Brady Sillman; Aditya N Bade; Zhiyi Lin; Diana L Palandri; Nagsen Gautam; Yazen Alnouti; Harris A Gelbard; JoEllyn McMillan; R Lee Mosley; Benson Edagwa; Howard E Gendelman; Santhi Gorantla
Journal:  J Clin Invest       Date:  2017-01-30       Impact factor: 14.808

3.  MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.

Authors:  Magdalene Ameka; Michael P Kahle; Mathew Perez-Neut; Saverio Gentile; Ahmed A Mirza; Bruce D Cuevas
Journal:  Biochem J       Date:  2014-11-15       Impact factor: 3.857

4.  Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis.

Authors:  Kyoko Tomita; Rohit Kohli; Brittany L MacLaurin; Petra Hirsova; Qianqian Guo; Luz H Gutierrez Sanchez; Harris A Gelbard; Burns C Blaxall; Samar H Ibrahim
Journal:  JCI Insight       Date:  2017-08-03

Review 5.  The regulatory function of mixed lineage kinase 3 in tumor and host immunity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 13.400

6.  Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.

Authors:  Kun Hyoe Rhoo; Megan Granger; Joynita Sur; Changyong Feng; Harris A Gelbard; Stephen Dewhurst; Oksana Polesskaya
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

7.  Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1.

Authors:  Fu-Chao Liu; Huang-Ping Yu; Yu-Ting Syu; Jia-You Fang; Chwan-Fwu Lin; Shih-Hsin Chang; Yen-Tung Lee; Tsong-Long Hwang
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

8.  Neutrophils Derived from Genetically Modified Human Induced Pluripotent Stem Cells Circulate and Phagocytose Bacteria In Vivo.

Authors:  Lisa R Trump; Ramesh C Nayak; Abhishek K Singh; Sana Emberesh; Ashley M Wellendorf; Carolyn M Lutzko; Jose A Cancelas
Journal:  Stem Cells Transl Med       Date:  2019-02-21       Impact factor: 6.940

9.  Chemical Composition and Immunomodulatory Activity of Essential Oils from Rhododendron albiflorum.

Authors:  Igor A Schepetkin; Gulmira Özek; Temel Özek; Liliya N Kirpotina; Andrei I Khlebnikov; Mark T Quinn
Journal:  Molecules       Date:  2021-06-15       Impact factor: 4.411

10.  URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Gang Zhang; R Lee Mosley; Harris A Gelbard; Howard E Gendelman
Journal:  J Neuroinflammation       Date:  2018-05-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.